DelveInsight’s, “Amyotrophic Lateral Sclerosis Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis pipeline landscape. It covers the Amyotrophic Lateral Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Amyotrophic Lateral Sclerosis research. Learn more about our innovative pipeline today! @ Amyotrophic Lateral Sclerosis Pipeline Outlook

Key Takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report

• On 10 October 2025, InFlectis BioScience conducted a clinical trial is an exploratory study, designed to show a signal of efficacy of IFB-088 through ALSFRS-R, MITOS and King’s College. Respiratory function will be followed through SVC. Biomarkers and quality of life will also be evaluated throughout the study.
• On 10 October 2025, Zydus Therapeutics Inc. initiated a study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Usnoflast administered to adult subjects with Amyotrophic Lateral Sclerosis followed by 16 weeks open label extension study.
• On 07 October 2025, Novartis Pharmaceuticals organized a Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ALS symptoms onset). The study comprises a core double-blind (DB) 40-week treatment period followed by an open label extension (OLE).
• On 06 October 2025, Helixmith Co. Ltd announced a phase I/II study designed to assess the safety and tolerability of intramuscular injections of VM202 inpatients with Amyotrophic Lateral Sclerosis. Study enrollment will be staged. Enrollment will be halted after the sixth subject qualifies for treatment. A Data Safety Monitoring Board will conduct a safety evaluation after the first patient treated completes the Day 60 follow-up evaluation and the five other sequentially enrolled subjects complete at least the Day 30 follow-up. Enrollment will be suspended until a formal recommendation to proceed (or not proceed) is made by the Data Safety Monitoring Board.
• DelveInsight’s Amyotrophic Lateral Sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Amyotrophic Lateral Sclerosis treatment.
• The leading Amyotrophic Lateral Sclerosis Companies such as Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB and others.
• Promising Amyotrophic Lateral Sclerosis Pipeline Therapies such as Dazucorilant 300 mg, AP-101, Fasudil (WP-0512), RT001, ARGX-119, AMX0035, ION363, ANX005, and others.

Stay informed about the cutting-edge advancements in Amyotrophic Lateral Sclerosis treatments. Download for updates and be a part of the revolution in Neurology care @ Amyotrophic Lateral Sclerosis Clinical Trials Assessment

The Amyotrophic Lateral Sclerosis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Amyotrophic Lateral Sclerosis Pipeline Report also highlights the unmet needs with respect to the Amyotrophic Lateral Sclerosis.

Amyotrophic Lateral Sclerosis Overview

Amyotrophic Lateral Sclerosis, also known as “Lou Gehrig disease,” is a neurodegenerative disease of the motor neurons. No single etiology has been proven; rather, multiple pathways (both heritable and sporadic) have been shown to result in unmistakably similar disease entities. ALS necessarily affects both upper and lower motor neurons with variable patterns of onset, most commonly beginning with signs of lower motor neuron degeneration within proximal limbs. As it is a progressive disease, it will eventually lead to paralysis and, inevitably, death.

Amyotrophic Lateral Sclerosis Emerging Drugs Profile

• MN-166: MediciNova

MN-166 is a first-in-class, orally bioavailable, small molecule glial attenuator that suppresses pro-inflammatory cytokines IL-1ß, TNF-a, and IL-6, and may upregulate the anti-inflammatory cytokine IL-10. It has additionally been shown to be a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of ALS.

• RNS60: Revalesio

RNS60 is being developed to provide disease modifying and potentially restorative treatments for neurological diseases. The drug activates intracellular signaling pathways to increase mitochondrial biogenesis and function and reduce inflammation. RNS60 safely protects neurons and oligodendrocytes and modulates the activity of immune cells to restore homeostasis. RNS60 has been granted Orphan Drug and Fast Track designations for ALS from the US Food and Drug Administration. The drug is currently being evaluated under Phase II clinical trial for the treatment of ALS.

• VM202: Helixmith

VM202 is an innovative gene therapy drug that provides fundamental treatment through tissue regeneration. The drug is injected along the peripheral nerves and their branches, the internal production of HGF may protect nerves and promote the growth of neurons while also ameliorating atrophic conditions. The US FDA granted orphan drug and fast track designation to VM202. The drug is currently being evaluated under Phase II clinical trial for the treatment of ALS.

• QRL-201: QurAlis Corporation

QRL-201 is a first-in-class therapeutic product candidate aiming to restore STMN2 expression in ALS patients. STMN2 is a well-validated protein important for neural repair and axonal stability, the expression of which is significantly decreased in nearly all ALS patients. QRL-201 rescues STMN2 loss of function in QurAlis ALS patient-derived motor neuron disease models in the presence of TDP-43 pathology. The drug is currently being evaluated under Phase I clinical trial for the treatment of ALS.

Learn more about Amyotrophic Lateral Sclerosis Drugs opportunities in our groundbreaking Amyotrophic Lateral Sclerosis research and development projects @ Amyotrophic Lateral Sclerosis Unmet Needs

The Amyotrophic Lateral Sclerosis Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Amyotrophic Lateral Sclerosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Amyotrophic Lateral Sclerosis Treatment.
• Amyotrophic Lateral Sclerosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Amyotrophic Lateral Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Amyotrophic Lateral Sclerosis market.

Amyotrophic Lateral Sclerosis Companies

Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB and others.

Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Amyotrophic Lateral Sclerosis Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Discover the latest advancements in Amyotrophic Lateral Sclerosis treatment by visiting our website. Stay informed about how we’re transforming the future of neurology @ Amyotrophic Lateral Sclerosis Market Drivers and Barriers, and Future Perspectives

Scope of the Amyotrophic Lateral Sclerosis Pipeline Report

• Coverage- Global
• Amyotrophic Lateral Sclerosis Companies- Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB and others.
• Amyotrophic Lateral Sclerosis Pipeline Therapies- Dazucorilant 300 mg, AP-101, Fasudil (WP-0512), RT001, ARGX-119, AMX0035, ION363, ANX005, and others.
• Amyotrophic Lateral Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Amyotrophic Lateral Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Amyotrophic Lateral Sclerosis Pipeline on our website @ Amyotrophic Lateral Sclerosis Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Amyotrophic Lateral Sclerosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Amyotrophic Lateral Sclerosis– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II/III)
11. MN-166: MediciNova
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. QRL-201: QurAlis Corporation
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Amyotrophic Lateral Sclerosis Key Companies
21. Amyotrophic Lateral Sclerosis Key Products
22. Amyotrophic Lateral Sclerosis- Unmet Needs
23. Amyotrophic Lateral Sclerosis- Market Drivers and Barriers
24. Amyotrophic Lateral Sclerosis- Future Perspectives and Conclusion
25. Amyotrophic Lateral Sclerosis Analyst Views
26. Amyotrophic Lateral Sclerosis Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight